Lanreotide · source year
3 selected, source-linked Lanreotide records carrying a 2014 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
3 selected records.
3 represented types.
3 distinct public records.
Cited chronology
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗